AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial
Sakib Burza(Unknown), Krishna Pandey(Rajendra Memorial Research Institute of Medical Sciences), Naresh Gill(National Center for Disease Control), Neâl Alexander(University of London), Amit Harshana, Fabiana Alves(Drugs for Neglected Diseases Initiative), Alan de Lima Pereira, Deepak Kumar(All India Institute of Medical Sciences Jodhpur), Pradeep Das(Rajendra Memorial Research Institute of Medical Sciences), Chandra Shekhar Lal(Rajendra Memorial Research Institute of Medical Sciences), Vikash Kumar, Vishal Goyal(Chandigarh University), Neena Verma(Rajendra Memorial Research Institute of Medical Sciences), Shahwar Kazmi(University of Karachi), Suman Rijal(Nepal Cancer Hospital and Research Center), Bharat Rewari(National AIDS Control Organisation), Estrella Lasry(Médecins Sans Frontières), Vidya Nand Ravi Das(Rajendra Memorial Research Institute of Medical Sciences), Raman Mahajan
Cited by 53
Related Papers
Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
|Nature Human Behaviour|2020|445
α <sup>+</sup> -Thalassemia protects children against disease caused by other infections as well as malaria
|Proceedings of the National Academy of Sciences|1997|302
Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial
|The Lancet|2004|239
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
|Clinical Microbiology Reviews|2018|218
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
|PLoS neglected tropical diseases|2017|78